History shows that inventions invariably build on earlier findings that are recombined and improved upon.
“Most of the things we use every day are inventions that no single human being could ever design within her lifetime,” biologist Joe Henrich, of the University of British Columbia, stated in an article for Scientific American. “Rather than the product of individual innovators, these inventions can be thought of as the product of our societies. Innovations rely on individuals learning from others – in that way, human society functions like a collective brain.”
In the world of pharmaceutical research, scientists are currently tackling some of the world’s most complex health problems, creating treatment options for diseases for which no effective therapies were previously available. These include developing vaccines for emerging health threats, custom gene therapies for cancer patients, and giving sufferers of chronic diseases, such as rheumatoid arthritis, new options to improve their quality of life.
Recognizing that solving these problems requires collaboration and knowledge sharing, Merck KGaA, Darmstadt, Germany, recently launched a network of “collaborative labs” to help partners troubleshoot and identify how to most quickly, safely, and efficiently bring their proof-of-concept, biopharmaceutical products to market. At these M Lab™ Collaboration Centers, in 10 locations and counting across the world, our scientists provide innovators who want to bring a new drug to market with technical expertise, education, and training. They help troubleshoot production issues and provide access to world class equipment. M Lab™ Collaboration Centers support customers who are looking for the technical experience and expertise of our scientists and technicians on finding solutions to the challenges of their individual biopharmaceutical processes.